Quality Improvement Work (AstraZeneca Sponsorship)

Optional component of the Royal College of Physicians’ (RCP) Clinicians as Leaders six-step programme for the new consultants

In order to be eligible to undertake the new consultants leadership programme at the reduced cost, participants will be expected to: (1) agree to deliver their Quality Improvement work in the specified timescale; (2) align your Quality Improvement work to AstraZeneca’s six Medical Missions (see details below) and (3) present your completed Quality Improvement programme case study either as an oral or poster presentation to AstraZeneca and RCP (AstraZeneca and RCP may choose to disseminate this work wider across the NHS, with your prior agreement).

Why is Quality Improvement important to the NHS?

Dr Binita Kane

Consultant Respiratory Physician at Manchester University Foundation Trust; Associate Medical Director of the Manchester Local Care Organisation; Royal College of Physicians QI Faculty member.

“If you have ideas to challenge the status quo and the will to improve the healthcare system for the benefit of patients and staff, a knowledge of QI methodology gives you a framework to execute these reliably to create real and sustainable change.”

For more information about RCP Quality Improvement: [https://www.rcp.ac.uk/projects/rcp-quality-improvement-rcpqi](https://www.rcp.ac.uk/projects/rcp-quality-improvement-rcpqi)

Quality Improvement aligned to AstraZeneca’s six medical missions for clinical practice change

Binder Fagura

Head of UK external Scientific Engagement, Medical & Scientific Affairs, AstraZeneca UK Ltd

“AstraZeneca are proud to be united with the RCP behind six powerful medical missions that span across our priority long-term conditions. AstraZeneca are truly privileged to be part of change programmes in partnership with the NHS that have brought about transformational improvements in clinical outcomes for patients, reduced NHS waiting lists, reduced the NHS carbon footprint and generated savings for the NHS.”
AstraZeneca’s six medical missions for clinical practice change:

1. **Zero tolerance for asthma attacks**
   All patients deserve access to anti-inflammatory medicines from the start

2. **Eliminate Chronic Oral Corticosteroids (OCS) for asthma patients**
   Accelerate access to precision medicine, reduce OCS use by 90%

3. **Early biology-based treatment of Chronic Obstructive Pulmonary Disease**
   Early diagnosis, treatment, prevention of decline, cardiovascular complications and premature death

4. **Prevent onset of cardiorenal disease in Type 2 Diabetes**
   Treat beyond Haemoglobin A1C (HbA1C) to prevent onset of Heart Failure, Chronic Kidney Disease and premature death

5. **Eradicate unplanned admissions for heart failure**
   Early diagnosis and treatment in the community, prevention of disease progression and hospitalisations

6. **Reduce death and progression to End Stage Renal Disease (ESRD) in Chronic Kidney Disease**
   Early diagnosis and treatment, prevention of kidney function decline

AstraZeneca has provided sponsorship to: (i) support the development of the Quality Improvement case studies component of Royal College of Physicians’ (RCP) New Consultants Leadership programme; (ii) allow the RCP to offer the New Consultant Leadership programme at a reduced cost for those that undertake a Quality Improvement case study.

AstraZeneca has had no involvement with or input into the development of the content of any part of the New Consultants Leadership programme and will have no influence over: (i) the selection of candidates for the New Consultants Leadership programme or the Quality Improvement case studies; or (ii) the selection of the case studies that will be performed by new consultants choosing to take part in it. RCP will be responsible for the supervision of the consultants on the Quality Improvement programme and for ensuring that their case studies are aligned to the six AstraZeneca medical missions for healthcare practice change.

---

1. NHS Partnerships can be viewed at: https://www.astrazeneca.co.uk/about-us/working-with-the-nhs.html [Last Accessed October 2021];
2. Re-engineering the post-myocardial infarction medicines optimisation pathway. Khatib R, et. al. Open Heart 2018; can be found at: https://openheart.bmj.com/content/5/2/e000921.info [Last Accessed October 2021];
4. Details of the SENTINEL Project can be found at:http://www.hullasthma.co.uk [Last Accessed October 2021];